Highlighting the relevance of BC cell line models, the ER+ cell line MCF-7, which was established in 1973, was an essential tool for the development of fulvestrant as a therapeutic agent for the treatment of ER+ metastatic BC [10,11]. This evidence concerns the gene ESR1 and breast cancer.